首页> 美国卫生研究院文献>Internal Medicine >Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease
【2h】

Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease

机译:肝硬化慢性肾脏病患者中托伐普坦和速尿对体液分布的不同影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 73-year-old man with liver cirrhosis and advanced chronic kidney disease was admitted to our hospital due to bilateral lower leg edema and appetite loss. Furosemide to treat fluid retention markedly decreased extracellular water compared with intracellular water, but the addition of tolvaptan equally decreased both with a greater diuretic response than furosemide alone. Furthermore, tolvaptan administration increased the plasma colloid osmotic pressure, which might facilitate the shift of fluid from the extravascular space to the intravascular space. This is the first case showing different effects on the fluid distribution between furosemide and additional tolvaptan in the same patient.
机译:因双侧小腿浮肿和食欲不振而住院的一名73岁的肝硬化和晚期慢性肾脏病患者。与细胞内水相比,用于治疗体液滞留的速尿显着减少了细胞外水,但是与单独使用速尿相比,托伐普坦的添加均同样减少了利尿作用。此外,托伐普坦的给药增加了血浆胶体渗透压,这可能有助于流体从血管外空间转移到血管内空间。这是第一例对同一患者中速尿和其他托伐普坦之间的液体分布有不同影响的情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号